關節疼痛注射市場－全球產業規模、佔有率、趨勢、機會、預測：按注射類型、應用、地區和競爭格局分類，2021-2031年

全球關節疼痛注射劑市場預計將從 2025 年的 47.2 億美元成長到 2031 年的 73.9 億美元，複合年成長率為 7.76%。

這些治療方法包括將止痛藥和抗發炎藥物直接注射到關節腔，以緩解肌肉骨骼疼痛並改善活動能力。該領域的發展主要受全球人口老化和骨關節炎盛行率上升的驅動，從而導致對有效非手術治療方法的需求日益成長。根據英國關節炎協會的數據，到2025年，英國將有超過1000萬人患有關節炎，這凸顯了對能夠彌合口服藥物和侵入性手術之間療效差距的對症治療方法的迫切需求。

然而，關節內注射皮質類固醇的長期安全性問題在市場中面臨許多挑戰。反覆注射此類藥物會帶來關節感染和軟骨劣化等風險，這往往會阻礙其在臨床上的持續應用。因此，醫療機構不得不限制用藥頻率，這對注射療法領域的持續發展構成了重大挑戰。

市場促進因素

類風濕性關節炎和骨關節炎盛行率的上升是全球關節疼痛注射市場的主要驅動力。隨著世界人口老化，退化性關節疾病的負擔日益加重，對非手術緩解症狀的需求也隨之穩定成長。這種人口結構的變化迫使醫療保健系統優先考慮注射療法，例如透明質酸和皮質類固醇，並推遲疼痛管理和全膝關節置換術術等侵入性手術。根據美國疾病管制與預防中心 (CDC) 於 2025 年 6 月發布的報告《預防慢性疾病》，美國 20 歲及以上成年人的關節炎粗略盛行率將達到 27.9%，這凸顯了有效關節內治療對於提高工作效率和生活品質的迫切需求。

此外，全球肥胖率的飆升正在推動市場擴張，因為它加速了關節退化，並降低了關節炎的平均發病年齡。超重會對負重關節造成嚴重的機械壓力，加速軟骨破壞，並需要更早治療性介入。 2025年3月發布的《2025年世界肥胖地圖集》預測，2030年，全球肥胖成年人口將達到11.3億。這一趨勢與肌肉骨骼合併症的增加密切相關，迫使製藥公司擴大其疼痛管理產品組合。 ANICKA Therapeutics在2025年報告稱，其2024年骨關節炎疼痛管理產品的國際收入年增了17%，這反映了上述趨勢。

市場挑戰

全球注射型關節疼痛市場成長的主要障礙在於長期使用關節內注射皮質類固醇的安全隱患。雖然這些藥物能有效緩解暫時性疼痛，但由於軟骨劣化和關節感染等風險，其持續使用受到限制。因此，醫療專業人員不得不限制治療頻率，通常會為患者設定年度用藥次數上限。這種安全限制使得該療法難以成為慢性疼痛管理的永續解決方案，降低了每位患者的收入，並導致其市場滲透率低於可每日服用且無類似操作限制的口服鎮痛藥。

鑑於需要持續疼痛管理的患者群體龐大，這項限制尤為重要。根據美國疾病管制與預防中心（CDC）預測，到2025年，21.3%的美國成年人將被診斷出患有關節炎。雖然這數據凸顯了尋求緩解疼痛的大規模人群，但無法安全、頻繁地注射皮質類固醇卻成為服務提供的一大瓶頸。疾病的高發生率與治療方法頻率的限制之間的差距，直接阻礙了市場充分利用對有效肌肉骨骼治療方法的需求。

市場趨勢

隨著臨床醫生越來越重視組織修復而非暫時緩解症狀，整形外科生物製劑和再生醫學的日益普及正在重塑市場格局。這一趨勢包括將富血小板血漿 (PRP) 和透明質酸支架等生物解決方案應用於臨床，旨在修復受損軟骨並延緩人工關節重建。醫療機構正迅速將這些治療方法納入治療通訊協定，以解決關節退化的根本原因，而不僅僅是掩蓋疼痛。 Anika Therapeutics 在 2025 年 11 月發布的 2025 年第三季財報中指出，其再生醫學解決方案業務的營收成長了 25%。這主要得益於其完整性植入系統的市場成功以及 Hi-Alofast 在國際市場的持續拓展。

為了減輕臨床負擔並提高患者就醫便利性，單次注射關節內粘稠補充療法正在逐步推廣。傳統的多次注射療程需要患者反覆就醫，而單次注射高分子量透明質酸製劑只需一次給藥即可提供持續的治療效果。這種方法已成為膝骨關節炎治療的首選方案，提高了醫療機構的運作效率並增強了患者的依從性。根據Bioventus公司2025年第三季財報，其疼痛管理領域的全球銷售額成長了6.4%。這主要得益於美國市場對Durolaine（一種差異化的單次注射透明質酸療法）的強勁需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球關節疼痛注射市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 注射類型（類固醇關節注射、玻尿酸注射、富血小板血漿（PRP）注射、胎盤組織基質（PTM）注射等）
  • 依應用部位（肩/肘、膝/踝、脊椎關節、髖關節、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美關節疼痛注射市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲關節疼痛注射市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區關節疼痛注射市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲關節疼痛注射市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美關節疼痛注射市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球關節疼痛注射市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Anika Therapeutics Inc
• Bioventus LLC
• Ferring Pharmaceuticals Inc
• Sanofi SA
• Pfizer Inc
• Eli Lilly & Co
• Flexion Therapeutics Inc
• Teva Pharmaceutical Industries Ltd
• Zimmer Biomet Holdings, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The global market for joint pain injections is projected to expand from USD 4.72 billion in 2025 to USD 7.39 billion by 2031, reflecting a compound annual growth rate of 7.76%. These therapeutic procedures involve the direct delivery of analgesic or anti-inflammatory medications into the synovial joint space to alleviate musculoskeletal pain and enhance mobility. The sector's growth is primarily fueled by the aging global population and the rising prevalence of osteoarthritis, which creates a strong need for effective non-surgical management options. Data from Arthritis UK indicates that over 10 million individuals in the United Kingdom were living with arthritis in 2025, highlighting the critical demand for symptomatic relief therapies that bridge the gap between oral pharmaceuticals and invasive surgeries.

However, the market encounters a significant obstacle regarding the safety profile of long-term intra-articular corticosteroid use. Repeated administration of these agents carries risks such as joint infection and cartilage degradation, factors that often discourage sustained clinical application. Consequently, healthcare providers are compelled to restrict the frequency of usage, which poses a notable challenge to the consistent growth of the injection therapy sector.

Market Driver

The rising incidence of rheumatoid arthritis and osteoarthritis serves as the primary engine for the Global Joint Pain Injections Market. As the worldwide population ages, the burden of degenerative joint conditions increases, generating a steady demand for non-surgical symptom relief. This demographic shift forces healthcare systems to prioritize injectable therapies, such as hyaluronic acid and corticosteroids, to manage pain and postpone invasive procedures like total knee arthroplasty. A June 2025 report from the Centers for Disease Control and Prevention, titled 'Preventing Chronic Disease', noted that the crude prevalence of diagnosed arthritis among U.S. adults aged 20 and older reached 27.9%, underscoring the vital need for effective intra-articular treatments to support workforce productivity and quality of life.

Additionally, surging global obesity rates are accelerating joint degeneration and propelling market expansion by lowering the average age of arthritis onset. Excess body weight places severe mechanical stress on weight-bearing joints, hastening cartilage breakdown and necessitating earlier therapeutic intervention. In March 2025, the World Obesity Federation's 'World Obesity Atlas 2025' projected that the number of adults living with obesity globally would rise to 1.13 billion by 2030. This trend correlates with increased musculoskeletal comorbidities, prompting pharmaceutical developers to broaden their pain management portfolios. Reflecting this, Anika Therapeutics reported in 2025 that revenue for its international osteoarthritis pain management products grew by 17% in 2024 compared to the previous year.

Market Challenge

The principal hurdle restraining the growth of the global joint pain injections market is the safety concern surrounding the prolonged use of intra-articular corticosteroids. Although these agents offer effective temporary relief, their sustained administration is limited by risks such as cartilage degradation and joint infections. As a result, healthcare professionals are forced to cap the frequency of treatments, often restricting patients to a specific quota of injections per year. This safety ceiling prevents the therapy from becoming a continuous solution for chronic pain management, thereby limiting revenue volume per patient and reducing overall market penetration compared to oral analgesics, which can be taken daily without similar procedural constraints.

This restriction is particularly significant given the vast patient population requiring consistent pain management. According to the Centers for Disease Control and Prevention, 21.3% of adults in the United States had diagnosed arthritis in 2025. This statistic highlights a massive demographic seeking relief; however, the inability to safely administer corticosteroid injections frequently creates a major bottleneck in service delivery. The disparity between the high prevalence of the condition and the restricted usage frequency of the treatment directly hampers the market's ability to fully capitalize on the demand for effective musculoskeletal therapies.

Market Trends

The market is being reshaped by the adoption of orthobiologics and regenerative medicine, as clinicians increasingly prioritize tissue repair over temporary symptom management. This trend involves integrating biologic solutions, such as platelet-rich plasma and hyaluronic acid-based scaffolds, which are designed to restore damaged cartilage and delay joint replacement surgeries. Healthcare providers are swiftly incorporating these therapies into treatment protocols to address the root causes of joint degeneration rather than merely masking pain. In its 'Third Quarter 2025 Financial Results' from November 2025, Anika Therapeutics reported a 25% revenue increase in its Regenerative Solutions segment, driven largely by the market success of the Integrity Implant System and strong international adoption of Hyalofast.

A concurrent shift toward single-injection viscosupplementation regimens is gaining traction due to the demand for reduced clinical burden and greater patient convenience. Unlike traditional multi-injection courses that require repeated hospital visits, single-injection high-molecular-weight hyaluronic acid formulations provide sustained therapeutic benefits in a unified administration. This approach improves operational efficiency for medical practices and enhances patient compliance, making it a preferred option for managing knee osteoarthritis. According to Bioventus's November 2025 'Third Quarter Financial Results', global revenue for its Pain Treatments segment accelerated by 6.4%, primarily fueled by robust U.S. demand for Durolane, a differentiated single-injection hyaluronic acid therapy.

Key Market Players

• Anika Therapeutics Inc
• Bioventus LLC
• Ferring Pharmaceuticals Inc
• Sanofi SA
• Pfizer Inc
• Eli Lilly & Co
• Flexion Therapeutics Inc
• Teva Pharmaceutical Industries Ltd
• Zimmer Biomet Holdings, Inc.

Report Scope

In this report, the Global Joint Pain Injections Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Joint Pain Injections Market, By Type of Injection

• Steroid Joint Injections
• Hyaluronic Acid Injections
• Platelet-rich Plasma (PRP) Injections
• Placental Tissue Matrix (PTM) Injections
• Others

Joint Pain Injections Market, By Application

• Shoulder & Elbow
• Knee & Ankle
• Spinal Joints
• Hip Joint
• Others

Joint Pain Injections Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Joint Pain Injections Market.

Available Customizations:

Global Joint Pain Injections Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Joint Pain Injections Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Others)
  • 5.2.2. By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Joint Pain Injections Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Injection
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Joint Pain Injections Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Injection
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Joint Pain Injections Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Injection
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Joint Pain Injections Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Injection
      • 6.3.3.2.2. By Application

7. Europe Joint Pain Injections Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Injection
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Joint Pain Injections Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Injection
      • 7.3.1.2.2. By Application
  • 7.3.2. France Joint Pain Injections Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Injection
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Joint Pain Injections Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Injection
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Joint Pain Injections Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Injection
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Joint Pain Injections Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Injection
      • 7.3.5.2.2. By Application

8. Asia Pacific Joint Pain Injections Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Injection
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Joint Pain Injections Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Injection
      • 8.3.1.2.2. By Application
  • 8.3.2. India Joint Pain Injections Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Injection
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Joint Pain Injections Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Injection
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Joint Pain Injections Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Injection
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Joint Pain Injections Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Injection
      • 8.3.5.2.2. By Application

9. Middle East & Africa Joint Pain Injections Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Injection
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Joint Pain Injections Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Injection
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Joint Pain Injections Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Injection
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Joint Pain Injections Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Injection
      • 9.3.3.2.2. By Application

10. South America Joint Pain Injections Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Injection
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Joint Pain Injections Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Injection
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Joint Pain Injections Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Injection
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Joint Pain Injections Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Injection
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Joint Pain Injections Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Anika Therapeutics Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bioventus LLC
• 15.3. Ferring Pharmaceuticals Inc
• 15.4. Sanofi SA
• 15.5. Pfizer Inc
• 15.6. Eli Lilly & Co
• 15.7. Flexion Therapeutics Inc
• 15.8. Teva Pharmaceutical Industries Ltd
• 15.9. Zimmer Biomet Holdings, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer